本文選題：肝腫瘤 + 高血壓�。� 參考：《重慶醫(yī)學(xué)》2017年35期

【摘要】：目的評(píng)價(jià)原發(fā)性肝癌合并肝硬化門(mén)靜脈高壓者行經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞(TACE)聯(lián)合經(jīng)頸靜脈肝內(nèi)門(mén)體分流(TIPS)術(shù)的安全性及療效。方法收集該院2011年1月至2015年1月因肝癌合并肝硬化門(mén)靜脈高壓失代償行TACE聯(lián)合TIPS的患者22例作為聯(lián)合組,篩選僅行TACE治療而未行TIPS治療的肝癌合并肝硬化患者28例作為對(duì)照組。觀察兩組患者的治療療效及預(yù)后。結(jié)果 TIPS治療手術(shù)成功率為100%,術(shù)前門(mén)靜脈壓力為(38.4±7.6)cm H_2O,術(shù)后門(mén)靜脈壓力為(28.4±7.7)cm H_2O,差異有統(tǒng)計(jì)學(xué)意義(P0.05);術(shù)前門(mén)靜脈直徑為(16.2±2.5)mm,術(shù)后門(mén)靜脈直徑為(13.3±1.8)mm,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。術(shù)后1年支架通暢率為95%,2年通暢率為90%。對(duì)照組1年及2年再出血率分別為60.7%及78.5%,而聯(lián)合組為9.1%、13.6%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。聯(lián)合組1年累計(jì)生存率為81%,2年累計(jì)生存率為68%,中位生存時(shí)間為53個(gè)月;對(duì)照組1年累計(jì)生存率為78%,2年累計(jì)生存率為15%,中位生存時(shí)間為17個(gè)月,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論肝癌合并門(mén)靜脈高壓行TACE聯(lián)合TIPS治療能安全、有效地控制腫瘤發(fā)展,減少甚至消除門(mén)靜脈高壓癥候群,提高患者生活質(zhì)量及生存率。
[Abstract]:Objective to evaluate the safety and efficacy of transcatheter hepatic artery chemoembolization (TACEE) combined with transjugular intrahepatic portosystemic shunt (TIPS) in patients with primary liver cancer complicated with cirrhosis and portal hypertension. Methods from January 2011 to January 2015, 22 patients with liver cancer complicated with portal hypertension decompensated with TACE and TIPS were collected as the combined group. A total of 28 patients with liver cancer complicated with liver cirrhosis were selected as control group who were treated only with TACE but not treated with TIPS. To observe the curative effect and prognosis of the two groups. Results the success rate of TIPS was 100, the preoperative portal vein pressure was 38.4 鹵7.6)cm H2Oand the postoperative portal vein pressure was 28.4 鹵7.7)cm H2O.The difference was statistically significant (P 0.05), and the preoperative portal vein diameter was 16.2 鹵2.5mm, the postoperative portal vein diameter was 13.3 鹵1.8mm. the difference was statistically significant (P0.05). The patency rate of stent 1 year and 2 years was 95 and 90 respectively. The rebleeding rates in the control group were 60.7% and 78.5%, respectively, while those in the combined group were 9.1% and 13.613.60.The difference was statistically significant (P 0.05). The 1-year cumulative survival rate, 2-year cumulative survival rate and median survival time were 81, 68 and 53 months respectively in the combined group, and 78, 15 and 17 months in the control group, respectively. The difference was statistically significant (P 0.05). Conclusion TACE combined with TIPS can effectively control tumor development, reduce or even eliminate portal hypertension syndrome, and improve the quality of life and survival rate of HCC patients with portal hypertension.
【作者單位】： 重慶醫(yī)科大學(xué)附屬第二醫(yī)院放射科;
【分類號(hào)】：R575.2;R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 蔣明德;秦建平;;TIPS的臨床應(yīng)用再評(píng)價(jià)[J];世界華人消化雜志;2003年12期

2 徐克;鐘紅珊;;迎接TIPS發(fā)展的第二個(gè)春天[J];放射學(xué)實(shí)踐;2006年05期

3 Douglas M.Coldwell;;The role of TIPS in the management of portal hypertension:a new perspective[J];介入放射學(xué)雜志;2006年12期

4 湯偉;;常規(guī)DSA技術(shù)在TIPS中的應(yīng)用[J];現(xiàn)代醫(yī)藥衛(wèi)生;2009年16期

5 皇甫瑜;秦建平;戴立里;蔣明德;;TIPS并發(fā)癥的研究進(jìn)展[J];西南國(guó)防醫(yī)藥;2009年12期

6 原姍姍;韓國(guó)宏;柏明;何創(chuàng)業(yè);殷占新;王建宏;祁興順;楊志平;張偉;;TIPS治療肝硬化頑固性腹水的預(yù)后因素分析[J];臨床肝膽病雜志;2011年05期

7 陳家飛;李蓮;李榮軍;;3D旋轉(zhuǎn)DSA在TIPS中的臨床應(yīng)用[J];局解手術(shù)學(xué)雜志;2011年05期

8 梁和業(yè);高普均;荊雪;韓雪晶;張晗;;TIPS臨床應(yīng)用現(xiàn)狀[J];吉林醫(yī)學(xué);2006年11期

9 Eric López-Méndez;Daniel Zamora-Valdés;Mariana Díaz-Zamudio;Oscar F Fernández-Díaz;Lourdes ávila;;Liver failure after an uncovered TIPS procedure associated with hepatic infarction[J];World Journal of Hepatology;2010年04期

10 梁艷平;唐映梅;楊晉輝;尤麗英;;TIPS術(shù)后支架功能障礙的研究現(xiàn)狀[J];世界華人消化雜志;2013年04期

相關(guān)會(huì)議論文 前10條

1 楊建勇;向賢宏;;TIPS技術(shù)臨床應(yīng)用的新進(jìn)展[A];中華醫(yī)學(xué)會(huì)第十八次全國(guó)放射學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2011年

2 徐克;鐘紅珊;;迎接TIPS發(fā)展的第二個(gè)春天[A];第二屆醫(yī)學(xué)影像山東論壇論文集[C];2005年

3 王茂強(qiáng);高育t，

本文編號(hào)：1903673